Guardant Health, Inc. (NASDAQ:GH) CEO Amirali Talasaz Sells 100,000 Shares

Guardant Health, Inc. (NASDAQ:GH - Get Free Report) CEO Amirali Talasaz sold 100,000 shares of the business's stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $50.88, for a total value of $5,088,000.00. Following the sale, the chief executive officer owned 1,971,830 shares of the company's stock, valued at approximately $100,326,710.40. This represents a 4.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

Amirali Talasaz also recently made the following trade(s):

• On Monday, June 9th, Amirali Talasaz sold 77,853 shares of Guardant Health stock. The shares were sold at an average price of $50.09, for a total value of $3,899,656.77.
• On Friday, June 6th, Amirali Talasaz sold 39,751 shares of Guardant Health stock. The shares were sold at an average price of $50.07, for a total value of $1,990,332.57.
• On Thursday, June 5th, Amirali Talasaz sold 1,680 shares of Guardant Health stock. The shares were sold at an average price of $50.00, for a total value of $84,000.00.
• On Thursday, May 1st, Amirali Talasaz sold 106,784 shares of Guardant Health stock. The shares were sold at an average price of $49.01, for a total value of $5,233,483.84.

Guardant Health Stock Performance

NASDAQ:GH traded down $0.53 during trading on Wednesday, reaching $50.18. The company's stock had a trading volume of 1,843,706 shares, compared to its average volume of 2,158,033. The firm has a market cap of $6.22 billion, a price-to-earnings ratio of -14.80 and a beta of 1.44. The firm has a 50 day moving average of $45.35 and a 200-day moving average of $42.83. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $53.42.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.08. The business had revenue of $203.47 million for the quarter, compared to the consensus estimate of $189.91 million. The business's revenue was up 20.8% compared to the same quarter last year. During the same quarter last year, the business posted ($0.46) EPS. Equities research analysts forecast that Guardant Health, Inc. will post -2.9 earnings per share for the current fiscal year.

Institutional Trading of Guardant Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Jones Financial Companies Lllp increased its stake in shares of Guardant Health by 43.5% during the fourth quarter. Jones Financial Companies Lllp now owns 2,696 shares of the company's stock valued at $82,000 after buying an additional 817 shares during the period. SBI Securities Co. Ltd. purchased a new position in shares of Guardant Health during the fourth quarter valued at approximately $43,000. Charles Schwab Investment Management Inc. increased its stake in shares of Guardant Health by 1.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,016,533 shares of the company's stock valued at $31,055,000 after buying an additional 13,395 shares during the period. SWS Partners increased its stake in shares of Guardant Health by 44.3% during the fourth quarter. SWS Partners now owns 120,888 shares of the company's stock valued at $3,693,000 after buying an additional 37,126 shares during the period. Finally, Aigen Investment Management LP increased its stake in shares of Guardant Health by 35.9% during the fourth quarter. Aigen Investment Management LP now owns 25,957 shares of the company's stock valued at $793,000 after buying an additional 6,854 shares during the period. Institutional investors own 92.60% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on GH. Mizuho upped their price target on Guardant Health from $60.00 to $65.00 and gave the stock an "outperform" rating in a report on Friday, June 13th. Stephens reiterated an "overweight" rating and set a $55.00 price target on shares of Guardant Health in a report on Wednesday, March 26th. Scotiabank reiterated an "outperform" rating on shares of Guardant Health in a report on Monday, May 5th. Stifel Nicolaus upped their price target on Guardant Health from $53.00 to $60.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Finally, Canaccord Genuity Group upped their price target on Guardant Health from $60.00 to $65.00 and gave the stock a "buy" rating in a report on Thursday, May 1st. Twenty-one research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $53.76.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.